In concordance with this idea, studies of MET TKI resistance in NSCLC have demonstrated that while the specific mechanisms of resistance vary, they often result in dependence on MYC activity, both in vitro and in vivo [141,142]. The gene discussed is MET; the disease is non-small cell lung carcinoma.